Centessa Pharmaceuticals plc
CNTA · NASDAQ
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Revenue | $0 | $6,853 | $0 | $0 |
| % Growth | -100% | – | – | – |
| Cost of Goods Sold | $0 | $0 | $0 | $0 |
| Gross Profit | $0 | $6,853 | $0 | $0 |
| % Margin | – | 100% | – | – |
| R&D Expenses | $150,244 | $124,405 | $155,083 | $96,322 |
| G&A Expenses | $50,811 | $53,731 | $55,200 | $43,009 |
| SG&A Expenses | $50,811 | $53,731 | $55,200 | $43,009 |
| Sales & Mktg Exp. | $0 | $0 | $0 | $0 |
| Other Operating Expenses | $0 | $0 | $1,980 | $235,536 |
| Operating Expenses | $201,055 | $178,136 | $212,263 | $374,867 |
| Operating Income | -$201,055 | -$171,283 | -$212,263 | -$374,867 |
| % Margin | – | -2,499.4% | – | – |
| Other Income/Exp. Net | -$31,858 | -$4,858 | -$4,691 | -$6,919 |
| Pre-Tax Income | -$232,913 | -$176,141 | -$216,954 | -$381,786 |
| Tax Expense | $2,844 | -$25,056 | -$747 | $114 |
| Net Income | -$235,757 | -$151,085 | -$216,207 | -$381,900 |
| % Margin | – | -2,204.7% | – | – |
| EPS | -2.06 | -1.57 | -2.31 | -4.24 |
| % Growth | -31.2% | 32% | 45.5% | – |
| EPS Diluted | -2.06 | -1.57 | -2.31 | -4.24 |
| Weighted Avg Shares Out | 114,473 | 96,178 | 93,401 | 89,988 |
| Weighted Avg Shares Out Dil | 114,473 | 96,178 | 93,401 | 89,988 |
| Supplemental Information | – | – | – | – |
| Interest Income | $14,016 | $10,476 | $244 | $0 |
| Interest Expense | $10,090 | $9,906 | $7,277 | $2,549 |
| Depreciation & Amortization | $942 | $810 | $131 | $34 |
| EBITDA | -$221,881 | -$165,425 | -$209,546 | -$139,297 |
| % Margin | – | -2,413.9% | – | – |